… trials for disease modification in Parkinson’s disease (PD) … a precision medicine approach,
which customises treatments … Furthermore, a new drug that facilitates protein function may …

… was associated with a reduction in Unified Parkinson’s Disease Rating Scale (UPDRS) motor
… for PD symptoms has opened up avenues for new treatment modalities, and it now seems …

… Evaluation of new drugs is monitored carefully in clinical trials. According to the United
States Food and Drug Administration, the purposes of phase I are safety and dosage; …

… of new drug-based therapies for the neurodegenerative condition of Parkinson’s disease
(PD… This progress included both “symptomatic treatments” (ST – improves/reduces symptoms of …

… Our goal is to provide an update of cholinergic systems and changes in Parkinson's disease
and isolated REM sleep behaviour disorder, a Parkinson's disease prodrome. We discuss …

… The development of new treatments has been slow since the US FDA approval in 1970 of
levodopa, the primary symptomatic therapy (ST) [6– 8]. Amantadine, monoamine oxidase type …

… new treatment methods, as well as improvements to old ones. Pharmacological, surgical, and
therapeutic treatments … both the established and new possibilities for PD treatment that can …

… disease modifying drugs provide cautious optimism that more effective therapies are on the
horizon. Emerging therapies, such as new symptomatic drugs, … 63 as well as emerging and …

… no cure or disease-modifying drugs for the treatment of these … of new treatments for
neurodegenerative diseases, several … in the search for new drugs for the treatment of AD and PD. …

… Our hope is that this report will provide some insights into the different approaches to
target PD and explore emerging novel treatment options. We also aim to raise awareness …